<DOC>
	<DOCNO>NCT00706862</DOCNO>
	<brief_summary>The purpose study determine whether combination talactoferrin , carboplatin paclitaxel improve progression free survival overall survival patient non-small cell lung cancer compare combination paclitaxel carboplatin alone</brief_summary>
	<brief_title>Safety Efficacy Talactoferrin Addition Standard Chemotherapy Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Confirmed locally advance metastatic nonsmall cell lung cancer unresectable At least 1 unirradiated target lesion measurable RECIST Adequate hematologic , renal hepatic function ECOG 0,1 Able understand sign Informed Consent Presence brain metastasis , unless patient receive brain irradiation , include adequate stereotactic radiosurgery , least 4 week prior randomization , stable , asymptomatic , steroid least 3 week prior randomization Received prior systemic anticancer therapy NSCLC History allergic reaction compound similar chemical biologic composition talactoferrin chemotherapy drug Any gastrointestinal tract disease medical condition result inability take oral medication History malignancy except : ( ) adequately treat basal squamous cell carcinoma skin ; ( ii ) curatively treat , ) situ carcinoma uterine cervix , b ) prostate cancer , c ) superficial bladder cancer ; ( iii ) curatively treat solid tumor evidence disease â‰¥5 year Uncontrolled ischemic heart disease , uncontrolled symptomatic congestive heart failure Serious active infection Psychiatric illness/social situation would limit study compliance Other uncontrolled serious chronic disease condition investigator 's opinion could render compliance followup protocol problematic Concurrent radiotherapy radiotherapy within 4 week prior randomization previous radiotherapy indicator site ( site follow determination response ) Concurrent systemic corticosteroid therapy within 4 week prior randomization , except prophylactic use steroid prior paclitaxel administration Known HIV positive active antiretroviral therapy Known Hepatitis B surface antigen positive hepatitis C positive Receipt investigational medication within 4 week prior randomization Pregnant lactating patient , fertile female patient positive pregnancy test , fertile female patient unwilling use adequate contraception treatment 30 day completion treatment Sexually active male patient unwilling practice contraception participate study 30 day completion treatment Legal incapacity limit legal capacity , unless authorization grant legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Talactoferrin</keyword>
	<keyword>Dendritic cell recruiter activator</keyword>
	<keyword>DCRA</keyword>
	<keyword>Immunomodulatory agent</keyword>
	<keyword>Lactoferrin</keyword>
</DOC>